Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 209

1.

Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers.

Creighton CJ, Fountain MD, Yu Z, Nagaraja AK, Zhu H, Khan M, Olokpa E, Zariff A, Gunaratne PH, Matzuk MM, Anderson ML.

Cancer Res. 2010 Mar 1;70(5):1906-15. doi: 10.1158/0008-5472.CAN-09-3875.

2.

[Expression and significance of microRNAs in the p53 pathway in ovarian cancer cells and serous ovarian cancer tissues].

Zhang Q, He XJ, Ma LP, Li N, Yang J, Cheng YX, Cui H.

Zhonghua Zhong Liu Za Zhi. 2011 Dec;33(12):885-90. Chinese.

PMID:
22340095
3.

Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer.

Amir S, Ma AH, Shi XB, Xue L, Kung HJ, Devere White RW.

PLoS One. 2013 Apr 9;8(4):e61064. doi: 10.1371/journal.pone.0061064.

4.

Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.

Vilming Elgaaen B, Olstad OK, Haug KB, Brusletto B, Sandvik L, Staff AC, Gautvik KM, Davidson B.

BMC Cancer. 2014 Feb 11;14:80. doi: 10.1186/1471-2407-14-80.

5.

Functional analysis of miR-34c as a putative tumor suppressor in high-grade serous ovarian cancer.

Yu Z, Kim J, He L, Creighton CJ, Gunaratne PH, Hawkins SM, Matzuk MM.

Biol Reprod. 2014 Nov;91(5):113. doi: 10.1095/biolreprod.114.121988.

6.

MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features.

Lee H, Park CS, Deftereos G, Morihara J, Stern JE, Hawes SE, Swisher E, Kiviat NB, Feng Q.

World J Surg Oncol. 2012 Aug 27;10:174.

7.

MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary.

Lee CH, Subramanian S, Beck AH, Espinosa I, Senz J, Zhu SX, Huntsman D, van de Rijn M, Gilks CB.

PLoS One. 2009 Oct 2;4(10):e7314. doi: 10.1371/journal.pone.0007314.

8.

Adenovirus-mediated overexpression of p14(ARF) induces p53 and Bax-independent apoptosis.

Hemmati PG, Gillissen B, von Haefen C, Wendt J, Stärck L, Güner D, Dörken B, Daniel PT.

Oncogene. 2002 May 9;21(20):3149-61.

9.

Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo.

Mullany LK, Fan HY, Liu Z, White LD, Marshall A, Gunaratne P, Anderson ML, Creighton CJ, Xin L, Deavers M, Wong KK, Richards JS.

Oncogene. 2011 Aug 11;30(32):3522-36. doi: 10.1038/onc.2011.70.

10.

Alterations in the INK4a/ARF locus and their effects on the growth of human osteosarcoma cell lines.

Park YB, Park MJ, Kimura K, Shimizu K, Lee SH, Yokota J.

Cancer Genet Cytogenet. 2002 Mar;133(2):105-11.

PMID:
11943335
11.

miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma.

Dong R, Liu X, Zhang Q, Jiang Z, Li Y, Wei Y, Li Y, Yang Q, Liu J, Wei JJ, Shao C, Liu Z, Kong B.

Oncotarget. 2014 Nov 15;5(21):10816-29.

12.

Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma.

Zhou J, Gong G, Tan H, Dai F, Zhu X, Chen Y, Wang J, Liu Y, Chen P, Wu X, Wen J.

Oncol Rep. 2015 Jun;33(6):2915-23. doi: 10.3892/or.2015.3937.

PMID:
25962395
13.

Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes.

Lauvrak SU, Munthe E, Kresse SH, Stratford EW, Namløs HM, Meza-Zepeda LA, Myklebost O.

Br J Cancer. 2013 Oct 15;109(8):2228-36. doi: 10.1038/bjc.2013.549.

14.

p53-dependent activation of microRNA-34a in response to etoposide-induced DNA damage in osteosarcoma cell lines not impaired by dominant negative p53 expression.

Novello C, Pazzaglia L, Conti A, Quattrini I, Pollino S, Perego P, Picci P, Benassi MS.

PLoS One. 2014 Dec 9;9(12):e114757. doi: 10.1371/journal.pone.0114757.

15.

Expression of Interactive Genes Associated with Apoptosis and Their Prognostic Value for Ovarian Serous Adenocarcinoma.

Shin K, Kim KH, Yoon MS, Suh DS, Lee JY, Kim A, Eo W.

Adv Clin Exp Med. 2016 May-Jun;25(3):513-21. doi: 10.17219/acem/62540.

16.

miR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma.

Liu Z, Gersbach E, Zhang X, Xu X, Dong R, Lee P, Liu J, Kong B, Shao C, Wei JJ.

Mol Cancer Res. 2013 Nov;11(11):1314-25. doi: 10.1158/1541-7786.MCR-13-0131.

17.

Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer.

Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, Cogdell D, Nykter M, Broaddus R, Rodriguez-Aguayo C, Lopez-Berestein G, Liu J, Shmulevich I, Sood AK, Chen K, Zhang W.

Cancer Cell. 2013 Feb 11;23(2):186-99. doi: 10.1016/j.ccr.2012.12.020. Erratum in: Cancer Cell. 2013 May 13;23(5):705.

18.

Inhibition of Ovarian Epithelial Carcinoma Tumorigenesis and Progression by microRNA 106b Mediated through the RhoC Pathway.

Chen S, Chen X, Xiu YL, Sun KX, Zhao Y.

PLoS One. 2015 May 1;10(5):e0125714. doi: 10.1371/journal.pone.0125714.

19.

Herpes virus microRNA expression and significance in serous ovarian cancer.

Pandya D, Mariani M, McHugh M, Andreoli M, Sieber S, He S, Dowell-Martino C, Fiedler P, Scambia G, Ferlini C.

PLoS One. 2014 Dec 8;9(12):e114750. doi: 10.1371/journal.pone.0114750.

20.

Necdin, a p53-target gene, is an inhibitor of p53-mediated growth arrest.

Lafontaine J, Rodier F, Ouellet V, Mes-Masson AM.

PLoS One. 2012;7(2):e31916. doi: 10.1371/journal.pone.0031916.

Items per page

Supplemental Content

Support Center